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An autoimmune disease with features of human SLE can be induced in some
normal mice during a graft-vs.-host reaction (GVHR),' referred to as SLE-like
graft-vs.-host disease (SLE-like GVHD) . In particular, injection of lymphocytes
from DBA/2 mice into (C57BL X DBA/2)F1 (BDF,) mice causes the appearance
of antibodies to dsDNA with consequent immune complex glomerulonephritis
(ICGN) (1, 2) . The autoantibodies are primarily produced by BDF1 B cells (3-
5) . Minimum requirements forthe production of autoantibodies are the presence
of Lyt-1+,2- T cells in the donor innoculum (6) and incompatibility between
parent strains at either the I-A (7) or I-E (8) major histocompatibility locus. No
requirement for recipient T cells has been demonstrated, although some studies
suggest that recipientT cells may suppress autoimmunity in SLE-likeGVHD (3,
5) . Using this model, we have examined the hypothesis that autoimmunity in
SLE-like GVHD is regulated by recipient T helper/inducer (L3T4+) and/or T
suppressor/cytotoxic (Lyt-2+) cells . This was possible because of the recent
demonstration that these cells can be selectively and permanently deleted in vivo
by treatment with mAbs to the lymphocyte subsets, after adult thymectomy (9) .
Our results demonstrate a requirement for recipient Lyt-2+ cells in the devel-
opment of autoimmunity in SLE-likeGVHD . Moreover, in this model, recipient
Lyt-2+ cells regulate the engraftment of donor cells . Recipient L3T4+ cells do
not significantly alter the outcome of the disease and have little or no effect on
engraftment of donor cells. This is the first direct demonstration that recipient
Lyt-2+ cells regulate donor cell engraftment in the parent-into-F, GVHR and
that they are required for autoimmunity during theGVHR .
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Materials and Methods
Mice.
￿
4-6-wk-old female DBA/2 (H-2d) and (C57BL/6 X DBA/2)F, (BDF,) (H-2
b/d)
mice, free of Sendai virus and mouse hepatitis virus, were purchased from Simonsen
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'Abbreviations used in this paper: BGG, bovine gamma globulin ; BUN, blood urea nitrogen ;
GVHD, graft-versus-host disease; GVHR, graft-versus-host reaction ; ICGN, immune complex glo-
merulonephritis; LN, lymph node .
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Laboratory, Gilroy, CA or Charles River Breeding Laboratories, Inc., Wilmington, MA,
and were housed in the animal care facility at the San Francisco Veterans Administration
Medical Center. Groups of 8-12 mice were used for each variable examined.
In Vivo Depletion of Lymphocyte Subsets.
￿
Sustained depletion of L3T4+ or Lyt-2+
lymphocyte subsets in vivo was achieved by using the method of Cobbold et al . (9). Briefly,
mice were thymectomized under pentobarbitol anesthesia at 4-6 wk of age and were
allowed to recover for 3 wk before intraperitoneal injection with anti-L3T4 (GK1 .5) or
anti-Lyt-2 .2 (2.43) rat IgG2b mAbs, two 0 .5-mg doses, 1 wk apart. Control groups
received either a rat mAb to chicken OVA (2C7, IgG2a) or saline, as indicated. After 4
wk, mice were bled for fluorescence analysis of circulating lymphocytes to quantitate cell
depletion. If, at this point, target cells were detectable at >2% of blood lymphocytes,
animals were considered to be incompletely thymectomized and were not used. This
analysis excluded 0 of 10 mice treated with anti-L3T4 and 2 of 10 mice treated with anti-
Lyt-2.
Induction of GVHR.
￿
Donor lymphocytes from DBA/2 mice were prepared from spleen
and lymph node (LN) cells, as follows: The inguinal, mesenteric, and cervical LN were
minced in cold RPMI 1640, passed through No. 40 wire mesh, and filtered through
loosely packed cotton wool. Spleen cells were passed through No. 40 wire mesh before
mixing with LN cells at a spleen cell/LN cell ratio of 2:1 . The cells were suspended in
PBS at room temperature before injection. BDF, mice received two injections, 1 wk apart,
of 6 x 10' live DBA/2 cells, in 0.4 ml, via the lateral tail vein. In the Results, the date of
the first injection is day 0; the second injection is day 7 .
Assessment of Autoimmunity.
￿
To assess autoimmunity during the GVHR, blood and
urine were collected from individual mice every other week after the first injection of
parental cells to measure (a) serum antibodies to poly(dA)-(dT), (b) proteinuria, and (c)
blood urea nitrogen (BUN). At the same time, mice were weighed and examined for
ruffling of fur and for diarrhea, evidence for acute GVHD .
Serum Antibodies to poly(dA)-(dT). Antibodies to poly(dA)-(dT) were quantified by
ELISA by a modification of the method of Fish and Ziff (10), who demonstrated that
poly(dA)-(dT) detects antibodies to dsDNA. For the ELISA, Microtest III microtitration
plates (Falcon Labware, Oxnard, CA) were sequentially exposed at room temperature to
the following reagents (all in 0.1 M Tris-HCI buffer, pH 7.2, with five distilled water
washes between each): (a) 75 A1/well of poly-L-lysine, 50 wg/ml, (Sigma Chemical Co., St.
Louis, MO) for 1 h; (b) 75,al/well of poly(dA)-(dT), 20 Ag/ml (Sigma Chemical Co.) for 1
h ; (c) 300 Al/well of BSA, 20 mg/ml (Sigma Chemical Co.) for 20 min; (d) 75 ,1/well of
serum samples from individual mice serially diluted in buffer containing 10 mg/ml BSA
and 20 mg/ml bovine gamma globulin (BGG) (Sigma Chemical Co.) for 1 h; (e) 300 al/well
of 20 mg/ml BSA for 20 min; (f) 75 Al/well of peroxidase-conjugated goat anti-mouse
Ig, 4 ug/ml (Cooper Biomedical, Inc., Malvern, PA) in buffer supplemented with BSA
and BGG, as in step d for 1 h . After washing, 75 Al/well of O-phenylenediamine, 1 mg/ml
(Zymed Laboratories, San Francisco, CA) and 0.3 tag/ml H202 in 0.1 M citrate phosphate
buffer, pH 5.0, were then added in the dark at room temperature . The reaction was
stopped after 10 min with 75 kl/well of2 N H2SO4. Absorbance at 490 nm was quantitated
by the use of an ELISA reader (model EL 308 ; Bio-Tek Instruments, Inc., Burlington,
VT) . Serum from adult MRL-lpr/lpr and normal, age-matched, BDF, mice served as
positive and negative controls, respectively.
Proteinuria. Urine samples were obtained at the same time as serum samples to
quantify protein by the use of Albustix (Miles Laboratories Inc., Elkhart, IN). This allows
an approximation by colorimetry of proteinuria as follows: trace, 10 mg/dl; 1+, 30 mg/dl;
2+, 100 mg/dl; 3+, 300 mg/dl; 4+, >_2,000 mg/dl. Normal mice were found to transiently
express up to 2+ proteinuria by this method . Therefore, a value of 3+ or 4+ was
considered indicative of pathologic proteinuria. To reflect the development of proteinuria
in all mice, the values at each time point reflect the level of proteinuria in surviving mice,
as well as the last measure of proteinuria in deceased mice.
Blood Urea Nitrogen.
￿
BUN was determined in individual mice using a CentrifiChem
System 400 (Union Carbide Corp., Danbury, CT). All mice had values of <30 mg/dl atHARPER ET AL.
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TABLE I
Antibodies Used for Fluorescence Analysis
the time of grafting. A value of ?30 mg/dl was therefore considered abnormal for
comparison of groups by X2 analysis, using the BUN at the end of the study or, in the
event of death, the last measured BUN.
Fluorescence Analysis ofLymphocyte Subpopulations.
￿
Peripheral blood was obtained from
individual mice by retroorbital bleeding into heparinized pipettes. Mononuclear cells were
separated by centrifugation over Lymphocyte-M (Cedarlane Laboratories Ltd., Ontario,
Canada). Lymphocyte subsets were identified by use of a FRCS II (Becton Dickinson &
Co., Sunnyvale, CA). For single-color analysis, fluorescein-conjugated mAbs were used.
For simultaneous two-color analysis, using a single laser, one mAb was conjugated with
fluorescein and the other with biotin, followed by exposure to avidin-conjugated phycoer-
ythrin (Streptavidin; Becton Dickinson & Co.). Analysis was restricted to lymphocytes on
the basis of size, as determined by forward-angle light scatter. Fluorescence is expressed
in arbitrary units with the use of a logarithmic scale. mAbs used for analysis are listed in
Table I. All reagents were centrifuged at 100,000 g for 5 min immediately before use.
Statistics.
￿
Data were analyzed using the X2 test with the Yates correction, except for
comparison of anti-poly(dA)-(dT) antibody titers, which used Student's t test, and for
comparison of changes in lymphocyte subpopulations, which used Wilcoxon's rank sum
test.
Results
Sustained, Selective Depletion of T Cell Subsets (L3T4 + or Lyt-2+) from BDF1
Mice. When BDF, mice were thymectomized and treated with two doses of rat
mAb to either L3T4 or Lyt-2, there was sustained, selective depletion of target
cells 4 wk after the last injection of mAb (Table II). In groups that were not
thymectomized before treatment with target-cell mAb (Table II, groups A4 and
134), partial recovery of target cell populations was observed. At this point, no
rat mAb could be detected on circulating lymphocytes from any group by FACS
staining with mAb to rat K chain (results not shown). Thus, at the time of donor
(parental) cell injection, recipient mice were selectively depleted of target lym-
phocyte subsets and had no evidence for persistence of antilymphocyte mAbs.
As will be discussed below, the selective loss of recipient T cell subsets persisted
after donor cell engraftment .
Depletion ofLyt-2+ Cells, but Not L3T4 + Cells, from BDF1 Recipient Mice Prevents
Autoimmunity after Injection with Donor DBA/2 Lymphocytes. Injection of DBA/2
cells into nonthymectomized, non-mAb-treated BDF1 recipient mice led to the
rapid appearance of antibodies to poly(dA)-(dT) that peaked 4-6 wk after the
first injection of donor cells, and were sustained for as long as 12 wk (Fig. 1).
Thymectomy alone or thymectomy followed by an irrelevant rat mAb (anti-
Antibody
Surfa gc e~anti- Cell population identified Reference
30-H12 Thy-1 .2 T cells 11
GK1 .5 L3T4 T helper/inducer cells 12
53-6 Lyt-2 T suppressor/cytotoxic cells 13, 14
Ra3-6132 13220 B cells 15
34-5-8S H-2Dd H-2d cells 16
138-24-3 H-2Kb H-26 cells 17
MAR-18.5 - Cells bearing rat mAb 18660
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TABLE II
Lymphocyte Subpopulations in BDF, Mice After Thymectomy and/or
Treatment with Antilymphocyte Antibodies
Blood lymphocytes from individual mice (8-10/group) were analyzed 4
wk after the last treatment with mAb, as described in the Materials and
Methods. Groups Al-A4 were treated and examined concurrently, as
were groups B1-B4.
* Results are the mean percent of circulating lymphocytes, defined on the
basis of size, as described in the Materials and Methods.
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FIGURE 1 .
￿
Geometric mean titer (X SEM) of
antibodies to poly(dA)-(dT) in groups of BDF,
recipient mice treated by (A) thymectomy fol-
lowed by anti-Lyt-2 mAb (solid boxes), no thy-
mectomy followed by saline (open bars), or thy-
mectomy followed by saline (hatched bars); and
(B) thymectomy followed by anti-L3T4 mAb
(solid bars), no thymectomy followed by saline
(openbars) or thymectomy followed by rat mAb
against chicken OVA (hatched bars). Sera from
individual mice in each group were assayed by
ELISA, as described in Materials and Methods.
Week 0 indicates the time of the first injection
of donor DBA/2 lymphocytes. Results of sera
from normal mice as negative controls fell in
the <1 :10 region and are not shown.
Group Thymec-
tomy
mAb
treatment
L3T4 Lyt-2 B220
Al + Anti-Lyt-2 29 1 61
A2 - - 30 21 38
A3 + - 22 14 52
A4 - Anti-Lyt-2 41 4 38
B1 + Anti-L3T4 1 21 71
B2 - - 27 17 55
B3 + - 23 16 56
B4 - Anti-L3T4 8 30 58a
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FIGURE 2.
￿
Frequency of proteinuria a.3+ (300 mg/dl) in groups of
BDF, recipients treated by (A) thymectomy followed byanti-Lyt-2 mAb
(squares), no thymectomy followed by saline (circles) or thymectomy
followed by saline (triangles); and (B) thymectomy followed by anti-
L3T4 mAb (squares), no thymectomy followed by saline (circles) or
thymectomy followed by rat mAb to chicken OVA (triangles). Week 0
indicates the time of the first injection of donorDBA/2 lymphocytes.
Each point represents proteinuria in surviving mice as well as the last
measurement of proteinuria in deceased mice (see Materialsand Meth-
ods).
chicken OVA) in BDF, recipients did not significantly alter levels of autoanti-
bodies (Fig. 1). However, when thymectomized mice were depleted of Lyt-2'
cells, no antibodies to poly(dA)-(dT) were detected at any time (Fig. IA, solid
bars; p < 2.5 x 10-7 compared with thymectomy only, by time-adjusted analysis).
In contrast, depletion of L3T4' cells from thymectomized BDF, recipients had
no significant effect on autoantibody production (Fig. 1 B, solid bars).
The lack of autoantibodies in BDF, mice depleted of Lyt-2' cells wasassociated
with lack of pathologic proteinuria; only an occasional mouse in this group
developed transient proteinuria during the 12-wk experiment (Fig. 2A; p < 0.05
compared with either control at 8, 10, and 12 wk). In contrast, >80% of mice in
all other groups had developed proteinuria by 12 wk (Fig. 2).
Of mice depleted of Lyt-2' cells, only 1 of 8 developed an abnormal BUN
during the 12 wk after donor cell injection (Fig. 3A1), compared with 8 of 10
thymectomized BDF, recipients depleted of L3T4+ cells (Fig. 3B1; p < 0.025)
and compared with 13 of 18 nonthymectomized, non-mAb-treated BDF, recip-
ients (Fig. 3, A2 and B2; p < 0.025). A significant rise in BUN was also seen in
10 of 19 recipients subjected to thymectomy only or thymectomy followed by an
irrelevant rat mAb (anti-chicken OVA) (Fig. 3, A and B; 0.05 < p < 0.1). 6 of
the 9 mice in these groups that did not achievea significantly elevated BUN died
between 4 and 8 wk after donor cell grafting. Because these mice developed
autoantibodies, it is likely that the biweekly sampling interval used for BUN
measurement may have missed significantly higher BUN levels immediately
before death.
Increased Engraftment ofDonor L3T4+ and Lyt-2' Lymphocytes Occurs in BDF,
Mice Depleted ofHost Lyt-2' Lymphocytes. 4 wk after the first injection of donor
DBA/2 lymphocytes, near the peak of autoantibody production in controls,662
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FIGURE 3.
￿
BUN from BDF1 recipient mice treated with (A I) thymectomy followed by anti-
Lyt-2 mAb, (BI) thymectomy followed by anti-L3T4 mAb, (A2 and B2) no thymectomy
followed by saline (A3) thymectomy followed by saline or (B3) rat mAbagainst chickenOVA.
Linesbegin at week 0, representing the first injection of donor DBA/2 lymphocytes, and end
at the last measured BUN (see Materialsand Methods).
blood cells from individual mice were analyzed forT cell subsetsof both recipient
and donor origin. Simultaneous two-color FACS analysis was used, one stain
being either anti-H-2Kb or anti-H-21)", the other strain being anti-L3T4 or anti-
Lyt-2. The use of anti-H-2Kb provided a sensitive distinction between recipient
and donor T cell subsets as demonstrated in Fig. 4, while anti-H-2Kd identified
the sum of donor and recipient cells. By this analysis, it was demonstrated that
BDF1 recipients depleted of Lyt-2+ cells had a substantial increase in the engraft-
ment of both L3T4+ and Lyt-2' donor lymphocytes as well as a decrease in
recipient L3T4+ cells (Table 111). In these mice, virtual repopulation by donor
cells occurred, with 95% of circulating T lymphocytes being of parental origin,
compared with <_35% in all other groups (p < 0.005). Despite this extensive
engraftment of donor T cells, recipient mice depleted of Lyt-2+ cells not only
lacked autoimmunity, but also failed to develop signs of acute GVHD, as assessed
by loss of weight, ruffling of fur, or development of diarrhea. Moreover, none
of the mice in this group died .
In contrast to the depletion of Lyt-2+ cells, depletion of recipient L3T4+ cells
had little or no effect on donor cell engraftment (Table I1I). Similarly, in BDF1
mice subjected to thymectomy but not treated with mAb, there was no effect on
donor cell engraftment, although host T cells were diminished (Table III). We
conclude that depletion of recipient Lyt-2+ cells, but not L3T4+ cells, permits
enhanced engraftment of parental cells.TABLE III
Host and DonorTLymphocyte Subpopulations in BDF, Mice After Injection with Donor Cells
HARPER ET AL.
Blood lymphocytes from individual mice (8-10/group) were analyzed 4 wk after the first injection
of DBA/2 cells, as described in Materialsand Methods .
* Host cells are defined as those reacting with anti-H-2k' mAb (hybridoma B8-24-3), as shown in
Fig . 4 .
Donor cells are defined as those reacting with anti-H-213' (hybridoma 34-5-8S), but not reacting
with anti-H-2K'mAb(hybridoma B8-24-3) .
§ Results are the mean percent of all circulating lymphocytes, defined on the basis ofsize, as described
in Materials and Methods. In recipients treated with anti-Lyt-2, both L3T4' and Lyt-2' host cells
are diminished, reflecting nearly complete replacement by donor T cells .
Discussion
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FIGURE 4 . Representative contour
plot of simultaneous dual-color
FACS analysis of blood cells from a
BDF, recipient ofDBA/2 cells . Host
cells are identified by mAb to H-26
(A and B), which donor cells lack (C
and D) . In this example, host L3T4'
cells (B) are distinguishedfrom donor
L3T4' cells (D) .
To test the hypothesis that recipient T cells may regulate the development of
autoimmunity in SLE-like GVHD, we permanently depleted F, recipient mice of
their L3T4+ (helper/inducer) or Lyt-2+ (suppressor/cytotoxic) T cells before the
induction of the parent-into-F, GVHR . Depletion of recipient Lyt-2' T cells
abrogated autoimmunity and permitted enhanced engraftment of both L3T4+
and Lyt-2+ donor cells. Depletion of recipient L3T4{ cells did not significantly
alter autoimmunity and had little or no effect on engraftment of donor cells .
Similarly, a rat mAb not reactive with mouse antigens had no effect on autoim-
munity or donor cell engraftment .
Group Thm c-
tomy mAb
Host
L3T4
cells*
Lyt-2
Donor
L3T4
cells*
Lyt-2
T cells
ofdonor
origin
Auto-
immunity
Al + Anti-Lyt-2 1§ 1 32 9 95 -
A2 - None 21 16 8 2 21 +
A3 + None 8 13 8 3 34 +
B1 + Anti-L3T4 3 16 6 1 27 +
B2 - None 19 16 4 1 13 +
B3 + None 9 12 6 1 25 +664
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Previous studies (3, 5) have addressed the role of recipient T cells in the
development of autoimmunity in SLE-like GVHD. In these studies, groups of
adult-thymectomized, lethally irradiated BDF, recipients were reconstituted with
fetal liver cells before injection with DBA/2 lymphocytes. In these T cell-
depleted mice, a higher percentage developed ICGN and proteinuria than in
normal BDF, recipients or in adult-thymectomized BDF, recipients. In addition,
fewer donor cells were required to induce disease. These findings suggest a
suppressive role for recipient T cells in SLE-like GVHD. Our studies, however,
did not demonstrate a suppressive role for recipient T cells. BDF, recipients
treated by thymectomy alone did show decreased survival, but they did not have
increased levels of autoimmunity.
In our studies, the mAbs used to deplete recipient T cell subsetsin vivo, before
grafting, did not remain to influence the engraftment of donor cells. First, in
control, nonthymectomized, BDF, mice treated by the same mAb protocol, there
was significant recovery of the target cell populations after 4 wk, the time of the
first injection of parent lymphocytes (Table 11). This indicates the absence of
functional anti-target cell mAbat this time . Second, in every mouse, fluorescence
analysis with a mAb to rat K chain demonstrated a lack of cell-surface rat mAb
(results not shown). Third, donor cell engraftment was unaltered in recipients
depleted of L3T4+ cells and was enhanced in recipients depleted of Lyt-2+ cells,
findings that are inconsistent with the presence of antilymphocyte mAbs at the
time of donor cell engraftment.
The enhanced engraftment of parental cells after depletion of recipient Lyt-
2+ cells excludes the possibility that the lack of autoimmunity in these mice is
due to an insufficiency of donor cells. It is possible either that the increased
engraftment suppressed autoimmunity or that recipient Lyt-2+ cells are directly
required forthe development ofautoimmunity. In favorofthe former possibility,
it has been previously demonstrated (reviewed in reference 19) that the engraft-
ment of specific donor T cell subset(s) during the GVHR correlates with the
form of GVHD observed in the BDF, recipient. Similarly, the GVHR differs
depending on whether there are differences at class I and/or class 11 major
histocompatibility antigens between the donor and host (7, 20-22) . With regard
to our model, Pals et al . (23, 24) have demonstrated that the development of
autoimmunity in BDF, recipients of DBA/2 cells is associated with engraftment
of donor L3T4' cells, but very few, if any, donor Lyt-2+ cells, a findingconfirmed
in our studies of untreated BDF, recipients (Table 111). In BDF, recipients of
cells from the C57 parent, both L3T4+ and Lyt-2+ donor cells engraft and there
is immune suppression rather than autoimmunity. Removal of Lyt-2+ cells from
the C57 parent innoculum converts the disease to an SLE-like GVHD (6). It is
therefore possible that donor Lyt-2+ cells kill or suppress autoreactive cells in
the host.
Our studies provide the first direct demonstration that Lyt-2+ cells influence
the engraftment of parental lymphocytes in F, recipients. Several studies (25-
27) have demonstrated that F, recipients can generate cytotoxic T cells directed
against parent cells. In BDF, recipients given C57 parent cells, F, anti-parent
cytotoxic cells have been shown to be Lyt-2' (28). In light of these findings and
ours, it seems likely that F, cytolytic Lyt-2+ cells can reduce engraftment ofHARPER ET AL.
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parental lymphocytes, as they do allogeneic lymphocytes (21, 29) . Ifso, this effect
is seemingly independent of recipient L3T4+ cells, because depletion of the latter
does not increase donor cell engraftment. The rejection of parental lymphocytes
by Lyt-2+ recipient cells is in contrast to rejection of parental hematopoietic cells,
which is mediated in F, mice not by T cells but by NK cells (30-32).
Summary
When lymphocytes from DBA/2 mice are transferred to (C57BL x DBA/2)F1
(BDF,) mice, the ensuing graft-vs.-host reaction (GVHR) causes an autoimmune
illness resembling human SLE. To examine the role of recipient T cells in this
process, BDF1 mice were depleted of L3T4+ or Lyt-2+ cells by thymectomy
followed by treatment with mAbs to L3T4 or Lyt-2. This produced sustained
depletion of these T cell subsets. Subsequent grafting with parental DBA/2
lymphocytes produced autoimmune disease in mice depleted of L3T4+ cells and
controls but not in mice depleted of Lyt-2+ cells. Analysis of blood lymphocytes
4 wk after donor cell transfer demonstrated that BDF1 recipients depleted of
Lyt-2+ cells were virtually repopulated with donor T lymphocytes, compared
with _<35% donor cell engraftment in all other groups. Thus, recipient Lyt-2+
cells influence both host cell engraftment and autoimmunity during the parent-
into-F, GVHR.
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